seekingalpha.com
Immunovia AB (publ) (IMMVF) Q4 2025 Earnings Call Transcript
Immunovia AB (publ) (IMMVF) Q4 2025 Earnings Call Transcript
IMMVFIMMVFOTC
Loading
Latest News
Loading news...
seekingalpha.com
Immunovia AB (publ) (IMMVF) Q3 2025 Earnings Call Transcript
Immunovia AB (publ) (OTC:IMMVF) Q3 2025 Earnings Call November 26, 2025 9:00 AM EST Company Participants Jeff Borcherding - Global Chief Executive Officer & President Conference Call Participants Niklas Elmhammer - Carlsquare AB, Research Division Presentation Jeff Borcherding Global Chief Executive Officer & President Good afternoon, good morning, and welcome to the Q3 interim report for Immunovia. I'm excited to speak with you today about the milestones we've achieved and the progress that we've made in our mission to save lives through early detection of pancreatic cancer.
prnewswire.com
Immunovia provides further positive data from the VERIFI study of its next-generation pancreatic cancer test
LUND, Sweden , March 24, 2025 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced additional results from the successful VERIFI study of its next-generation pancreatic cancer test, strengthening the company's position as it prepares to launch the pancreatic cancer blood test commercially. Immunovia's next-generation test detected significantly more cancers than CA19-9, a common biomarker for pancreatic cancer, in the study.
prnewswire.com
Immunovia to host a webcast to share more data from the successful VERIFI clinical validation study
LUND, Sweden , March 21, 2025 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, published positive results from the VERIFI clinical validation of its next-generation test for pancreatic cancer on March 19, 2025. As a follow up, Immunovia will host a webcast on Monday, March 24 at 3 pm CET.
prnewswire.com
Immunovia announces another successful clinical validation of its next-generation pancreatic cancer test
LUND, Sweden , March 19, 2025 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced positive results from the VERIFI study, the second clinical validation study of its next-generation pancreatic cancer test. The study met its primary endpoint, with the test successfully detecting 77% of stage I and II cases of pancreatic cancer.
prnewswire.com
Immunovia AB (Publ) presents Nomination Committee
LUND, Sweden , Jan. 8, 2025 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced the appointment of the Company's Nomination Committee. According to the instructions for the Nomination Committee of Immunovia AB (Publ), the Nomination Committee shall consist of four members, of which three should be appointed by the Company's three largest shareholders in terms of votes, and the fourth shall be the Chair of the Board of Directors.
prnewswire.com
Immunovia CEO and board members announce intention to fully exercise their TO2 warrants
LUND, Sweden , Dec. 18, 2024 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced its CEO and board members intend to exercise all TO2 warrants they received in the company's rights issue that was announced on May 20, 2024. Immunovia CEO Jeff Borcherding, one of the company's largest shareholders based on prior purchases, intends to exercise all warrants he purchased in the recent rights issue.
prnewswire.com
Immunovia presents data from model development study at meeting of the PRECEDE pancreatic cancer research consortium
SAN DIEGO , Nov. 7, 2024 /PRNewswire/ -- Immunovia (NASDAQ STOCKHOLM: IMMNOV), the pancreatic cancer diagnostics company, will present an update on its next-generation test at the annual meeting of the PRECEDE Consortium, a collaboration of 51 pancreatic centers worldwide conducting unprecedented research for the early detection of pancreatic cancer in individuals with increased risk for the disease. Immunovia will share results from studies of its next-generation test to detect stage 1 and 2 pancreatic cancer, including the discovery study, model-development study, and analytical validation.
prnewswire.com
Immunovia presents data from model development study at 2024 AACR Advances in Pancreatic Cancer medical conference
LUND, Sweden , Sept. 16, 2024 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today presented detailed model-development study results at the AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer (abstract #B027).
prnewswire.com
Immunovia announces updated financial calendar
LUND, Sweden , March 12, 2024 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq) (IMMNOV: Stockholm), the diagnostics company with the mission to increase pancreatic cancer survival rates through early detection, updates its financial calendar for 2024. Annual Report to be published April 25, 2024 Q1 Report, 2024 April 25, 2024 Annual General Meeting June 4, 2024 Q2 Report, 2024 August 22, 2024 Q3 Report, 2024 November 14, 2024 For more information, please contact: Karin Almqvist LiwendahlChief Financial Officer karin.almqvist.liwendahl@immunovia.com +46 709 11 56 08 Immunovia in brief Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection.
prnewswire.com
Immunovia to Significantly Restructure to Focus Resources on its Next-Generation Blood Test for Pancreatic Cancer Detection
LUND, Sweden , July 12, 2023 /PRNewswire/ -- Immunovia (Nasdaq Stockholm: IMMNOV), the diagnostics company focused on early detection of pancreatic cancer, today announced plans to restructure its operations. The company will cease commercialization of its IMMray PanCan-d test in the United States to focus its resources on the further development and clinical testing of the Company's promising next generation pancreatic cancer detection test.
prnewswire.com
Immunovia to present at Gilmartin Group's Emerging Growth Company Showcase
LUND, Sweden , Aug. 23, 2022 /PRNewswire/ -- Immunovia today announced it will participate in Gilmartin Group's Emerging Growth Company Showcase on August 31, 2022. Philipp Mathieu, CEO and President, and Jeff Borcherding, US CEO, are scheduled to present on Wednesday, August 31, 2022 at 9:00 am ET (15:00 pm CET).